Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction

F. Shen, L. A. Decosterd, M. Gander, S. Leyvraz, J. Biollaz, F. Lejeune

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

As a part of a pilot clinical study, a high-performance reversed-phase liquid chromatography analysis was developed to quantify temozolomide in plasma and urine of patients undergoing a chemotherapy cycle with temozolomide. All samples were immediately stabilized with 1 M HCl (1 + 10 of biological sample), frozen and stored at -20°C prior to analysis. The clean-up procedure involved a solid-phase extraction (SPE) of clinical sample (100 μl) on a 100-mg C18-endcapped cartridge. Matrix components were eliminated with 750 μl of 0.5% acetic acid (AcOH). Temozolomide was subsequently eluted with 1250 μl of methanol (MeOH). The resulting eluate was evaporated under nitrogen at RT and reconstituted in 200 μl of 0.5% AcOH and subjected to HPLC analysis on an ODS-column (MeOH-0.5% AcOH, 10:90) with UV detection at 330 nm. The calibration curves were linear over the concentration range 0.4-20 μg/ml and 2-150 μg/ml for plasma and urine, respectively. THe extraction recovery of temozolomide was 86-90% from plasma and 103-105% from urine over the range of concentrations considered. The stability of temozolomide was studied in vitro in buffered solutions at RT, and in plasma and urine at 37°C. An acidic pH (

Original languageEnglish (US)
Pages (from-to)291-300
Number of pages10
JournalJournal of Chromatography B: Biomedical Sciences and Applications
Volume667
Issue number2
DOIs
StatePublished - May 19 1995
Externally publishedYes

Fingerprint

temozolomide
Plasma (human)
High performance liquid chromatography
Plasmas
Chemotherapy
Liquid chromatography
Acetic Acid
Methanol
Nitrogen
Calibration
Recovery

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. / Shen, F.; Decosterd, L. A.; Gander, M.; Leyvraz, S.; Biollaz, J.; Lejeune, F.

In: Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 667, No. 2, 19.05.1995, p. 291-300.

Research output: Contribution to journalArticle

Shen, F. ; Decosterd, L. A. ; Gander, M. ; Leyvraz, S. ; Biollaz, J. ; Lejeune, F. / Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. In: Journal of Chromatography B: Biomedical Sciences and Applications. 1995 ; Vol. 667, No. 2. pp. 291-300.
@article{e2d4d0fe29f9453aa62226a8ead60f47,
title = "Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction",
abstract = "As a part of a pilot clinical study, a high-performance reversed-phase liquid chromatography analysis was developed to quantify temozolomide in plasma and urine of patients undergoing a chemotherapy cycle with temozolomide. All samples were immediately stabilized with 1 M HCl (1 + 10 of biological sample), frozen and stored at -20°C prior to analysis. The clean-up procedure involved a solid-phase extraction (SPE) of clinical sample (100 μl) on a 100-mg C18-endcapped cartridge. Matrix components were eliminated with 750 μl of 0.5{\%} acetic acid (AcOH). Temozolomide was subsequently eluted with 1250 μl of methanol (MeOH). The resulting eluate was evaporated under nitrogen at RT and reconstituted in 200 μl of 0.5{\%} AcOH and subjected to HPLC analysis on an ODS-column (MeOH-0.5{\%} AcOH, 10:90) with UV detection at 330 nm. The calibration curves were linear over the concentration range 0.4-20 μg/ml and 2-150 μg/ml for plasma and urine, respectively. THe extraction recovery of temozolomide was 86-90{\%} from plasma and 103-105{\%} from urine over the range of concentrations considered. The stability of temozolomide was studied in vitro in buffered solutions at RT, and in plasma and urine at 37°C. An acidic pH (",
author = "F. Shen and Decosterd, {L. A.} and M. Gander and S. Leyvraz and J. Biollaz and F. Lejeune",
year = "1995",
month = "5",
day = "19",
doi = "10.1016/0378-4347(95)00040-P",
language = "English (US)",
volume = "667",
pages = "291--300",
journal = "Journal of Chromatography B: Biomedical Sciences and Applications",
issn = "0378-4347",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction

AU - Shen, F.

AU - Decosterd, L. A.

AU - Gander, M.

AU - Leyvraz, S.

AU - Biollaz, J.

AU - Lejeune, F.

PY - 1995/5/19

Y1 - 1995/5/19

N2 - As a part of a pilot clinical study, a high-performance reversed-phase liquid chromatography analysis was developed to quantify temozolomide in plasma and urine of patients undergoing a chemotherapy cycle with temozolomide. All samples were immediately stabilized with 1 M HCl (1 + 10 of biological sample), frozen and stored at -20°C prior to analysis. The clean-up procedure involved a solid-phase extraction (SPE) of clinical sample (100 μl) on a 100-mg C18-endcapped cartridge. Matrix components were eliminated with 750 μl of 0.5% acetic acid (AcOH). Temozolomide was subsequently eluted with 1250 μl of methanol (MeOH). The resulting eluate was evaporated under nitrogen at RT and reconstituted in 200 μl of 0.5% AcOH and subjected to HPLC analysis on an ODS-column (MeOH-0.5% AcOH, 10:90) with UV detection at 330 nm. The calibration curves were linear over the concentration range 0.4-20 μg/ml and 2-150 μg/ml for plasma and urine, respectively. THe extraction recovery of temozolomide was 86-90% from plasma and 103-105% from urine over the range of concentrations considered. The stability of temozolomide was studied in vitro in buffered solutions at RT, and in plasma and urine at 37°C. An acidic pH (

AB - As a part of a pilot clinical study, a high-performance reversed-phase liquid chromatography analysis was developed to quantify temozolomide in plasma and urine of patients undergoing a chemotherapy cycle with temozolomide. All samples were immediately stabilized with 1 M HCl (1 + 10 of biological sample), frozen and stored at -20°C prior to analysis. The clean-up procedure involved a solid-phase extraction (SPE) of clinical sample (100 μl) on a 100-mg C18-endcapped cartridge. Matrix components were eliminated with 750 μl of 0.5% acetic acid (AcOH). Temozolomide was subsequently eluted with 1250 μl of methanol (MeOH). The resulting eluate was evaporated under nitrogen at RT and reconstituted in 200 μl of 0.5% AcOH and subjected to HPLC analysis on an ODS-column (MeOH-0.5% AcOH, 10:90) with UV detection at 330 nm. The calibration curves were linear over the concentration range 0.4-20 μg/ml and 2-150 μg/ml for plasma and urine, respectively. THe extraction recovery of temozolomide was 86-90% from plasma and 103-105% from urine over the range of concentrations considered. The stability of temozolomide was studied in vitro in buffered solutions at RT, and in plasma and urine at 37°C. An acidic pH (

UR - http://www.scopus.com/inward/record.url?scp=0029065472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029065472&partnerID=8YFLogxK

U2 - 10.1016/0378-4347(95)00040-P

DO - 10.1016/0378-4347(95)00040-P

M3 - Article

C2 - 7663702

AN - SCOPUS:0029065472

VL - 667

SP - 291

EP - 300

JO - Journal of Chromatography B: Biomedical Sciences and Applications

JF - Journal of Chromatography B: Biomedical Sciences and Applications

SN - 0378-4347

IS - 2

ER -